PreveCeutical Medical Inc (CSE:PREV, OTCMKTS:PRVCF) said Tuesday it has developed a way to convert phytocannabinoids extracted from the company's five cannabis strains from acid to neutral.
The Vancouver-based company said in a press release that it has confirmed the conversion of cannabidiolic acid (CBDA) and tetrahydrocannabinolic acid (THCA) to the neutral canabidiol (CBD) and tetrahydrocannabinol (THC). It added that no degradation was detected.
"Having optimized the conditions for comprehensive conversion of phytocannabinoids from acid to neutral forms opens the door to a wider product range for Preveceutical,” the company's chief research officer, Dr. Harendra Parekh, said in a statement.
PreveCeutical added that it has added five neutral cannabinoid extracts to its five acid cannabinoid extracts. The company plans to incorporate acid and neutral extracts into its soluble-gel drug delivery program.
On Monday, the company said it was encouraged by tests of nasal gel sprays to administer medical-based cannabis treatments of epilepsy, anxiety and depression.
Contact Dennis Fitzgerald at [email protected]